

# HEALTHCARE MONTHLY

SEPTEMBER 2019

*Our healthcare team architects market-defining outcomes for some of the most innovative medical device, life science and diagnostics, healthcare services and pharmaceutical companies in the world.*









BioTech / Pharma

Healthcare Services

Life Sciences / Diagnostics


Medical Devices

## HEADLINE TRANSACTIONS


	TARGET	ACQUIROR	ACQUISITION SYNOPSISIS
BioTech / Pharma	 Worldwide Rights to Otezla		<ul style="list-style-type: none"> <li>Amgen Inc. (NasdaqGS:AMGN) entered into a definitive agreement to acquire the worldwide rights to Otezla from Celgene Corporation (NasdaqGS:CELG) for \$13.4 billion</li> <li>Otezla is a leading treatment for plaque psoriasis and psoriatic arthritis with potential for treating other immune system related inflammatory diseases</li> <li>Amgen Inc. is an American multinational biopharmaceutical company, specializing in the development of human therapeutics</li> </ul>
	 Animal Health Division		<ul style="list-style-type: none"> <li>Elanco Animal Health Inc. (NYSE:ELAN) entered into a share and asset purchase agreement to acquire Bayer Animal Health for \$76 billion</li> <li>Bayer Animal Health engages in the research and development of products for animal health and pest control</li> <li>Elanco Animal Health Inc. develops products for companion and food animals</li> </ul>
Life Sci. / Diagnostics			<ul style="list-style-type: none"> <li>Permira Advisors LLC entered into a definitive agreement to acquire Cambrex Corporation (NYSE:CBM) for \$2.1 billion, a 47% premium</li> <li>Cambrex Corporation provides various products and services for the development of new and generic therapeutics worldwide</li> <li>Permira Advisors LLC is a UK based private equity firm operating internationally</li> <li>Implied Enterprise Value Multiples: 4.6x Revenue, 179x EBITDA</li> </ul>
Medical Devices			<ul style="list-style-type: none"> <li>Siemens Healthineers AG signed a definitive agreement to acquire Corindus Vascular Robotics, Inc. (AMEX:CVRS) for \$1.1 billion, a 76.9% premium</li> <li>Corindus Vascular Robotics, Inc. manufactures robotic-assisted systems for use in interventional vascular procedures</li> <li>Siemens Healthineers AG provides healthcare information technology products</li> <li>Implied Enterprise Value Multiples: 71.3x Revenue</li> </ul>

# HEALTHCARE GROWTH & VALUATION TRENDS


Enterprise Value / LTM Revenue




Enterprise Value / LTM EBITDA



LTM Revenue Growth




LTM Gross and EBITDA Margins\*



\*EBITDA Margins shown as the gray line.

LTM Stock Price Index



# SELECTED HEALTHCARE TRANSACTIONS

Target	Acquiror	BioTech / Pharma Transaction
BlueRock Therapeutics LP	Bayer Aktiengesellschaft	BlueRock Therapeutics LP develops engineered cell therapies in the fields of neurology Transaction Value: \$240 million and up to \$360 million in milestones

Modis Therapeutics, Inc.	Zogenix, Inc.	Modis Therapeutics, Inc. develops disease modifying therapies for rare genetic diseases Transaction Value: \$250 million and up to \$150 million in milestones
--------------------------	---------------	---

Cavion LLC	Jazz Pharmaceuticals plc	Cavion LLC develops therapies to restore the brain's natural rhythms by modulating overactive T-type calcium channels Transaction Value: \$52.5 million and up to \$260 million in milestones
------------	--------------------------	--

Target	Acquiror	Life Sci / Diagnostics Transaction
XynManagement, Inc.	CareDx, Inc	XynManagement, Inc. develops software for transplant quality tracking and Scientific Registry of Transplant Recipients (SRTR) reporting

Taxon Biosciences, Inc.	Lavie Bio Ltd.	Taxon Biosciences, Inc. develops microbiome-based transformative applications for the agriculture, life sciences and oil and gas industries
-------------------------	----------------	---

cytena GmbH	Cellink AB (publ)	cytena GmbH develops a laboratory device to separate single cells
-------------	-------------------	---

Target	Acquiror	Health Services Transaction
WebPT, Inc.	Warburg Pincus LLC	WebPT, Inc. develops electronic medical record and practice management solutions for physical therapists, occupational therapists and speech-language pathologists in the United States

ProKnow, LLC.	Elekta AB	ProKnow, LLC. designs and develops cloud-based software solutions to improve quality in radiation oncology worldwide
---------------	-----------	--

QxMD Software Inc.	WebMD Health Corp.	QxMD Software Inc. develops apps for healthcare professionals
--------------------	--------------------	---

Target	Acquiror	Medical Devices Transaction
Avedro, Inc.	Glaukos Corporation	Avedro, Inc. develops and commercializes products to treat ophthalmic disorders and conditions, primarily associated with corneal weakness Transaction Value: \$486 million

SentreHEART, Inc.	AtriCure, Inc.	SentreHEART, Inc. manufactures devices for remote delivery of sutures for closure of anatomic structures Transaction Value: \$40 million and up to \$260 million in milestones
-------------------	----------------	---

Collagen Matrix, Inc.	Linden LLC	Collagen Matrix, Inc. designs medical equipment and collagen for tissue and organ repair
-----------------------	------------	--

## Selected TM Capital Healthcare Experience

## TM Capital's Healthcare Industry Contacts



**James McLaren,**  
Managing Director  
jmclaren@tmcapital.com  
212.809.1414



**Michael Goldman,**  
Managing Director  
mgoldman@tmcapital.com  
212.809.1419



**Paul Smolevitz,**  
Managing Director  
psmolevitz@tmcapital.com  
212.809.1416